Jazz Pharmaceuticals (JAZZ): Cutting PT ~30% - Mizuho

November 9, 2016 6:23 AM EST
Get Alerts JAZZ Hot Sheet
Price: $100.94 -2.83%

Rating Summary:
    27 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 20 | Down: 30 | New: 24
Trade JAZZ Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) but cut her price target to $127.00 from $185.00.

The estimate and PT cuts reflect a 3Q:16 miss and disclosure of a potentially disappointing Xyrem life-cycle extension product. The analyst sharpened her pencil and became more conservative with her Xyrem assumptions and overall outlook. The new PT of $127 is based on lower pricing, higher discounts, and assumed competitive entry in 2022.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $106.19 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Irina Koffler

Add Your Comment